<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="39867">Valproic acid</z:chebi> (VPA), a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) inhibitor, is known to protect against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of VPA on blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) disruption were investigated in rats subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>Postischemic VPA treatment remarkably attenuated MCAO-induced <z:chebi fb="2" ids="33602">BBB</z:chebi> disruption and <z:hpo ids='HP_0002181'>brain edema</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Meanwhile, VPA significantly reduced MCAO-induced elevation of matrix metalloproteinase-9 (MMP-9), degradation of tight junction proteins, and nuclear translocation of nuclear factor-κB (NF-κB) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="199" ids="26708">Sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi>, another HDAC inhibitor, mimicked these effects of VPA </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings suggest that <z:chebi fb="2" ids="33602">BBB</z:chebi> protection by VPA involves HDAC inhibition-mediated suppression of NF-κB activation, MMP-9 induction, and tight junction degradation </plain></SENT>
</text></document>